Integra Lifesciences Holdings (IART) Touches $53.50 High on Jun, 19; Pioneer Tax Free Income Fund (PBF)’s Sentiment Is 1.14

June 19, 2017 - By Maria Brooks

The stock of Integra Lifesciences Holdings Corp (NASDAQ:IART) reached all time high today, Jun, 19 and still has $58.32 target or 9.00% above today’s $53.50 share price. This indicates more upside for the $4.05 billion company. This technical setup was reported by If the $58.32 PT is reached, the company will be worth $364.50M more. About 32,638 shares traded. Integra Lifesciences Holdings Corp (NASDAQ:IART) has risen 32.67% since June 19, 2016 and is uptrending. It has outperformed by 15.97% the S&P500.

PBF Energy Inc. is a holding company. The company has market cap of $2.56 billion. The Firm is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the United States. It has a 12.66 P/E ratio. The Firm operates through two divisions: Refining and Logistics.

Old West Investment Management Llc holds 7.47% of its portfolio in PBF Energy Inc for 438,362 shares. Knightsbridge Asset Management Llc owns 251,900 shares or 6.55% of their US portfolio. Moreover, Skytop Capital Management Llc has 5.88% invested in the company for 350,000 shares. The Massachusetts-based Baupost Group Llc Ma has invested 5.72% in the stock. Snow Capital Management Lp, a Pennsylvania-based fund reported 3.13 million shares.

Ratings analysis reveals 50% of PBF Energy’s analysts are positive. Out of 6 Wall Street analysts rating PBF Energy, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. PBF was included in 6 notes of analysts from October 11, 2016. The stock of PBF Energy Inc (NYSE:PBF) has “Neutral” rating given on Tuesday, October 11 by Credit Suisse. As per Monday, February 27, the company rating was downgraded by Morgan Stanley. The firm earned “Neutral” rating on Wednesday, April 5 by Goldman Sachs. Howard Weil downgraded the shares of PBF in report on Wednesday, October 19 to “Sector Outperform” rating. Wolfe Research upgraded the stock to “Outperform” rating in Monday, November 14 report. Tudor Pickering upgraded the stock to “Buy” rating in Tuesday, November 1 report.

About 120,061 shares traded. PBF Energy Inc (PBF) has declined 20.84% since June 19, 2016 and is downtrending. It has underperformed by 37.54% the S&P500.

Among 10 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Integra Lifesciences Holdings Corp. had 15 analyst reports since July 29, 2015 according to SRatingsIntel. JMP Securities upgraded the stock to “Mkt Outperform” rating in Friday, January 6 report. The firm has “Buy” rating by UBS given on Monday, December 12. The rating was maintained by Jefferies on Tuesday, May 30 with “Buy”. Barclays Capital maintained the stock with “Equalweight” rating in Thursday, June 2 report. Lake Street maintained Integra Lifesciences Holdings Corp (NASDAQ:IART) rating on Wednesday, August 26. Lake Street has “Hold” rating and $55.0 target. Barclays Capital maintained it with “Equal Weight” rating and $84 target in Friday, July 29 report. On Monday, August 24 the stock rating was downgraded by Zacks to “Hold”. Citigroup initiated the shares of IART in report on Thursday, November 12 with “Buy” rating. The rating was upgraded by Bank of America on Monday, September 21 to “Buy”. The firm has “Overweight” rating by JP Morgan given on Wednesday, July 13.

Integra LifeSciences Holdings Corporation is a medical technology company. The company has market cap of $4.05 billion. The Firm focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. It has a 63.41 P/E ratio. The Company’s divisions include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analysts await Integra Lifesciences Holdings Corp (NASDAQ:IART) to report earnings on July, 27. They expect $0.44 EPS, up 10.00% or $0.04 from last year’s $0.4 per share. IART’s profit will be $33.31M for 30.40 P/E if the $0.44 EPS becomes a reality. After $0.39 actual EPS reported by Integra Lifesciences Holdings Corp for the previous quarter, Wall Street now forecasts 12.82% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: